Valuation: Ind-Swift Laboratories Limited

Market Cap 31.24B 329M 294M 271M 247M 465M 473M 3.26B 1.28B 16.26B 1.23B 1.21B 51.98B P/E 2025
2.38x
P/E 2026 26.1x
Enterprise Value 27.03B 285M 254M 235M 214M 402M 409M 2.82B 1.11B 14.06B 1.07B 1.05B 44.97B EV / Sales 2025
0.12x
EV / Sales 2026 1.11x
Free-Float
33.96%
Yield 2025 *
-
Yield 2026 -
1 day+0.36%
1 week-0.46%
Current month-7.59%
1 month-5.02%
3 months+55.20%
6 months+172.45%
Current year+307.54%
1 week 345
Extreme 345
377.2
1 month 345
Extreme 345
424.75
Current year 87.25
Extreme 87.25
424.75
1 year 87.15
Extreme 87.15
424.75
3 years 68.72
Extreme 68.72
424.75
5 years 52.65
Extreme 52.65
424.75
10 years 15
Extreme 15
424.75
Manager TitleAgeSince
Chief Executive Officer 46 -
Chief Executive Officer 44 2011-06-14
Director of Finance/CFO - 2018-09-28
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 2010-03-22
Date Insider Type Main position Quantity % Market Cap. Importance
9/12/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%-0.46%+254.46%+293.05% 329M
+0.43%+6.59%+56.57%+107.01% 1,120B
+0.90%-2.25%+32.26%+67.33% 616B
+0.71%+3.24%+24.33%+91.20% 504B
-0.13%+5.98%+33.66%+50.18% 367B
+0.52%+0.24%+72.13%+43.10% 360B
-0.95%+4.70%+19.65%+42.71% 288B
-1.98%+3.73%-0.89%+10.43% 258B
-0.35%+4.25%+44.74%+52.51% 234B
-0.75%+3.32%+27.18%+96.05% 194B
Average -0.12%+3.21%+56.41%+85.36% 394.12B
Weighted average by Cap. +0.13%+3.83%+39.35%+72.89%

Financials

2025 2026
Net sales 5.62B 59.16M 52.84M 48.77M 44.45M 83.57M 84.96M 587M 231M 2.92B 222M 217M 9.35B 6.49B 68.37M 61.06M 56.36M 51.37M 96.57M 98.19M 678M 267M 3.38B 257M 251M 10.8B
Net income 2.5B 26.38M 23.56M 21.75M 19.82M 37.26M 37.89M 262M 103M 1.3B 98.99M 96.88M 4.17B 431M 4.54M 4.06M 3.74M 3.41M 6.42M 6.52M 45.07M 17.72M 224M 17.04M 16.68M 717M
Net Debt -4.27B -44.92M -40.13M -37.03M -33.76M -63.46M -64.52M -446M -175M -2.22B -169M -165M -7.1B -4.21B -44.37M -39.63M -36.57M -33.34M -62.67M -63.72M -440M -173M -2.19B -166M -163M -7.01B
Projected Income Statement - Annual - Ind-Swift Laboratories Limited
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,388
Date Price Change Volume
26-10-16 ₹359.25 +0.36% 309,979
26-10-15 ₹357.95 -3.18% 262,152
26-10-14 ₹369.70 +2.31% 354,561
26-10-13 ₹361.35 +0.08% 365,436
26-10-12 ₹361.05 +0.04% 305,213
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock